Thu, Jan 29, 2015, 6:34 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. (SNTA) Message Board

pharmatheway 72 posts  |  Last Activity: Jan 28, 2015 10:06 AM Member since: May 4, 2010
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Once again, he pointed to the data: “When the company combines Imbruvica (ibrutinib; Pharmacyclics Inc. [PCYC:NASDAQ]) with TG-1101, we now are approaching 100% response rates in chronic lymphocytic leukemia patients.” TG Therapeutics will start a Phase 3 study with ibrutinib later in 2015, and is looking at additional combinations. To give a sense of the potential, Pantginis shared the story of a patient who’d failed four previous Rituxan regimens and was about to be admitted to hospice. When put on TG-1101, she “converted to a complete response and hasn’t looked back yet. And that was as a monotherapy. So very, very promising.”

    TG Therapeutics’ second product, TGR-1202, is a PI3K kinase inhibitor, “again, a very hot target,” Pantginis said. The drug candidate is showing “very good response rates in lymphoma patients. What’s interesting is that this is a once-per-day drug, compared to twice-a-day with other drugs and, importantly, has not shown any of the liver toxicities seen with other PI3K inhibitors.” He also noted that TG, with a $689M market cap, was a top-performing stock last year in biotech and is the Focus Pick of his firm. “We think the stock has room to grow here. . .these hot targets are literally just scratching the surface from TG.”

    Sentiment: Strong Buy

  • Reply to

    Climate Change vs. Global Warming

    by speedydekker Jan 26, 2015 5:38 PM
    pharmatheway pharmatheway Jan 27, 2015 8:12 PM Flag

    Listen i live in south florida and when a hurricane is threatening they give you a cone of probability and if you are in that cone you better take it seriously because your life depends on it.weather particularly a storm is impossible to pin point land fall .It's no joke.

    Sentiment: Strong Buy

  • pharmatheway pharmatheway Jan 20, 2015 4:26 PM Flag

    Nice comeback today on good volume .I agree the best is yet to come.

    Sentiment: Strong Buy

  • pharmatheway pharmatheway Jan 16, 2015 10:18 AM Flag

    I like the confidence ,i see it playing out the same way as well .It's also good to hear that you listen to the CC yesterday .It was also interesting what Weiss said abut the 2 H of 2015 Initiate first clinical trial in Autoimmune Diseases.If this all plays out the way i think it will we will all be very happy .Patients is a virtue.Best of luck.

    Sentiment: Strong Buy

  • pharmatheway pharmatheway Jan 15, 2015 4:04 PM Flag

    Sorry but i believe the downward movement is nothing more than the markets in a tailspin .I believe that the conference was very positive ,If you didn't listen in you should .No liver toxicity to date ,IMO we will have better results than ibutinib alone and the autoimmune diseases will add great value to this stock.Swiss franc kill the market today.

    Sentiment: Strong Buy

  • Reply to

    Agressive recruiting for phase three

    by gokartronnie Jan 15, 2015 8:58 AM
    pharmatheway pharmatheway Jan 15, 2015 12:12 PM Flag

    autoimmune diseases is very attractive big deal in the making JMHO

    Sentiment: Strong Buy

  • Reply to

    Agressive recruiting for phase three

    by gokartronnie Jan 15, 2015 8:58 AM
    pharmatheway pharmatheway Jan 15, 2015 12:10 PM Flag

    Looks strong.IMO .TG-1101 Phas 3 Combination with ibutinib .High probability of success,suported by strong Phas 2 data .Conducted pursuant to SPA .Very attractive regimen:tolerability and efficacy. Proprietary Combination across CLL and NHL Pricing leverage. Additional Upside in autoimmune diseases and leadership in next generation triple therapy .BTK underway,IRAK4 before year end ,and others..2 years of cash .Burn 4 to 6 M per quarter. Cash 93.4M ( pro forma as of september 30,2014.STRONG BUY IMO

    Sentiment: Strong Buy

  • Reply to

    Agressive recruiting for phase three

    by gokartronnie Jan 15, 2015 8:58 AM
    pharmatheway pharmatheway Jan 15, 2015 9:40 AM Flag

    Aggressively recruit into the GENUINE Phase 3 Clinical Trial of TG-1101 in combination with ibrutinib, which is now open for enrollment
    Commence additional combination Phase 3 clinical trials, particularly for the Company's proprietary combination of TG-1101 plus TGR-1202 in patients with Chronic Lymphocytic Leukemia (CLL) and non-Hodgkin's Lymphoma (NHL)
    Commence clinical development for the Company's IRAK4 inhibitor program, expected in the second half of 2015
    Launch new triple therapy combination trials in addition to the currently enrolling Phase 1/2 trial of TG-1101 plus TGR-1202 plus ibrutinib
    Commence clinical development program for the treatment of autoimmune diseases across the Company's portfolio of development candidates
    Data update on Phase 1 and 2 clinical trials at major hematology/oncology conferences during 2015

    Sentiment: Strong Buy

  • Reply to

    RA

    by jjgiablue Jan 8, 2015 9:14 AM
    pharmatheway pharmatheway Jan 8, 2015 12:26 PM Flag

    Not relavent at all.Ublituximab is a monoclonal antibody that targets a unique epitope on the B-lymphocyte CD20 antigen. Ublituximab has been bioengineered to deliver enhanced clinical activity and potency. Developed for the treatment of B-cell proliferative disorders, including Non-Hodgkin's Lymphoma ("NHL") and Chronic Lymphocytic Leukemia ("CLL"), anti-CD20 antibodies target and aid in the depletion of B-lymphocytes. Anti-CD20 antibodies have also been shown to be effective in treating select autoimmune diseases such as Rheumatoid Arthritis ("RA") and Systemic Lupus Erythematosus ("SLE"), along with the neurological disorder Multiple Sclerosis ("MS").

    Sentiment: Strong Buy

  • Reply to

    Time to sell

    by richardkmilner Dec 30, 2014 5:44 PM
    pharmatheway pharmatheway Dec 30, 2014 7:21 PM Flag

    Patients is a virtue.When.Things happen when they are least expected.

    Sentiment: Strong Buy

  • pharmatheway pharmatheway Dec 26, 2014 12:01 PM Flag

    Long ago??Former Ku Klux Klan Officer Pleads Guilty to Committing Perjury During Investigation into Cross-Burning
    U.S. Department of Justice
    June 12, 2014

    Office of Public Affairs
    (202) 514-2007/TDD (202) 514-1888
    WASHINGTON—Pamela Morris, former secretary of a chapter of the Ku Klux Klan (KKK) in Ozark, Alabama, pleaded guilty today to committing perjury during a grand jury’s investigation into a racially motivated cross-burning in the U.S. District Court for the Middle District of Alabama.

    Morris, 46, admitted in plea documents that on February 20, 2013, she lied to a federal grand jury looking into a cross-burning committed by Steven Joshua Dinkle, Morris’ son and the leader of the local KKK, and Thomas Smith, another KKK member. On May 8, 2009, Dinkle and Smith burned a six-foot tall cross at the entrance to an African-American neighborhood in Ozark to threaten and intimidate residents. In sworn testimony before the grand jury, Morris made several false statements, including denying that she had been the secretary of the chapter or involved with the KKK at all.

    In pleading guilty, Morris admitted that she had been an officer of the KKK and that her testimony denying any connection to the organization was false. She further acknowledged that she knew Dinkle had committed the cross-burning. In addition, Morris admitted that she testified falsely to prevent the grand jury from learning about other KKK members who had information relevant to the investigation.

    A sentencing date has not yet been scheduled. Morris faces a statutory maximum sentence of five years in prison and a $250,000 fine.

    Dinkle pleaded guilty on February 3, 2014, to hate crime and obstruction of justice charges related to the cross-burning. On May 15, 2014, he was sentenced to serve 24 months in prison. Smith, Dinkle’s co-conspirator, pleaded guilty to conspiracy to interfere with housing rights on December 6, 2013. He is scheduled to be sentenced on August 19, 2014.

    “Defendant Morris lied under oath blatantly and repeatedly to hinder an investigation into a cross-burning that was committed to intimidate an entire community,” said Acting Assistant Attorney General Jocelyn Samuels for the Civil Rights Division. “The department will continue to hold accountable not only those who commit such acts of violence but also those who lie and obstruct the investigation into these crimes of intimidation.”

    “Ms. Morris lied to the grand jury in an attempt to protect herself and to protect a cross burner,” said U.S. Attorney George L. Beck Jr. for the Middle District of Alabama. “When someone testifies in court they swear to tell the truth. Unfortunately, Ms. Morris lied. For our system of justice to protect the rights of all, those who testify before the grand jury must provide accurate and honest information. If someone fails to tell the truth while under oath, we will prosecute them.”

    This case is being investigated by the FBI with the assistance of the Dale County Sheriff’s Office and the Ozark Police Department. The case is being prosecuted by Assistant U.S. Attorney Jerusha T. Adams of the Middle District of Alabama and Trial Attorney Chiraag Bains of the Civil Rights Division.

    Sentiment: Strong Buy

  • pharmatheway pharmatheway Dec 26, 2014 11:56 AM Flag

    The article was about Fox News' Double Standard For Right-Wing Cop Killers.

    Sentiment: Strong Buy

  • 0:02 EST - More healthcare company M&A in 2015? They've got the balance sheet for it. Pharmaceuticals' cash reserves jumped 11% y/y in 3Q to $217B, according to FactSet, money that could be used to continue the sector's dealmaking spree. Notably, the biggest hoarders are those that largely sat out 2014's M&A blitz: Johnson & Johnson (JNJ) added $7.8B to its cash on hand, Amgen (AMGN) $5.5B, Bristol Myers (BMY) $4.5B and Gilead (GILD) $4.2B.

    Sentiment: Strong Buy

  • pharmatheway by pharmatheway Dec 23, 2014 12:43 PM Flag

    Is a for profit co. also and near 52 week high .I say its time to short ESRX now..

    Sentiment: Strong Buy

  • Reply to

    Up Tomorrow IMO....My Take

    by starfe1l Dec 18, 2014 9:15 PM
    pharmatheway pharmatheway Dec 23, 2014 12:36 PM Flag

    You could thank Express Scripts for this drop in all drug and biotech stocks.I suppose Express Scrips who by the way a for profit co.also will be telling people if you can live or die.Take a tylenol for cancer or any condition will be the norm.

    Sentiment: Strong Buy

  • pharmatheway pharmatheway Dec 23, 2014 12:20 PM Flag

    So its ok when Express Scripts makes a profit but its not ok for drug co. what about the R&D expenses and all the work it takes from the lab to the market with any kind of drug from cancer and on and on .Who will do it? Express Scripts ? I think not the aren't doctors.Short this #$%$.

    Sentiment: Strong Sell

  • Reply to

    Thank you Express Scripts

    by gizmondo123 Dec 23, 2014 11:02 AM
    pharmatheway pharmatheway Dec 23, 2014 11:37 AM Flag

    Express Scripts is not my doctor! No consideration of R&D expenses and most of all peoples lives .Express Scripts will make the decision if you live or die.The are the doctors now.

    Sentiment: Strong Buy

  • pharmatheway pharmatheway Dec 23, 2014 10:52 AM Flag

    Agreed..Its ok for them to make a profit but not the co. that put the time and effort in finding life saving drugs.

    Sentiment: Strong Sell

  • pharmatheway by pharmatheway Dec 21, 2014 11:00 PM Flag

    This is good news as we need more options and Gilead is a smart company that has a strong track record on getting new and important drugs approved. It also has other small molecules including idelalisib that might make sense in combination therapies. The market seems to approve of the move as this joint effort should increase the likelihood we will be seeing ONO-4059 become commercially available.

    Ibrutinib is a great BTK inhibitor and has set the bar very very high in terms of its response rates and tolerability, but still it won't be the right choice for all patients due to some intolerance or adverse outcomes or lack of efficacy, so having another Bruton Tyrosine Kinase inhibitor option is something all patients should want.

    Sentiment: Strong Buy

  • pharmatheway pharmatheway Dec 19, 2014 3:26 PM Flag

    I'm glad i was wrong.And i never said anything about selling it was JMHO that i posted.

    Sentiment: Buy

SNTA
2.47+0.020(+0.82%)Jan 29 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.